Jake is a Venture Partner based in our San Francisco Bay Area office focused on working with emerging clinical biotechnology companies. He is a seasoned biotech executive and leader in the biopharmaceutical industry with a proven track record in company formation, strategy, executive and project leadership, and corporate and business development. Jake served as the Chief Business Officer of MyoKardia, Inc. prior to its acquisition by Bristol Myers Squibb in November 2020 for $13.1B.
Prior to this, he served as Senior Vice President, Finance and Corporate Development and Principal Financial Officer of MyoKardia having joined the company in 2014. Prior to joining MyoKardia, Jake served as Vice President, Business Operations and head of corporate development at Ablexis, LLC and as a principal at Third Rock Ventures. While at Third Rock Ventures, he was actively involved in a variety of leading biopharmaceutical companies including Agios Pharmaceuticals, Inc., CytomX Therapeutics Inc., and Global Blood Therapeutics, Inc.
Previously, Jake served in roles in the investment group at Royalty Pharma, the business development group at Endo Pharmaceuticals Inc. and as a management consultant at Putnam Associates. He currently serves on the Board of Attralus, Enliven Therapeutics, Phoenix Tissue Repair, Inc. and Arya Sciences Acquisition Corp V.
Jake holds a BS in Biology and a BA in Economics from Duke University and an MBA from Harvard Business School.